apd371
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2017 (NCT03155945)
Timeline
Indications
Mechanism of action
- Cannabinoid CB2 receptorAGONIST
CNR2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21- Mol. weight
- 357.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4175981 ↗
- ChEMBLCHEMBL3545329 ↗
Also known as
- apd371
- apd371
- apd-371
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04655599 | Phase 1 | Dec 31, 2020 | Arena Pharmaceuticals |
| NCT04043455 | Phase 2 | Jul 24, 2019 | Arena Pharmaceuticals |
| NCT03155945 | Phase 2 | May 18, 2017 | Arena Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arena Pharmaceuticals | For profit | 3 | 3 | 2 | 2017 |
1 organizations
Page 1 / 1